Dr Nick Ash, chief executive officer, Biofortuna Limited, previews the company’s visit to Med-Tech Innovation Expo.
Greg Harding Greg Harding Photography
First, what’s bringing you to Med-Tech Innovation Expo in June?
Well, it’s been a while since we have had the opportunity to get out and about and meet people, so first and foremost we are looking forward to that!
For the last two years we have been at the forefront of the fight against COVID, working with some of the world’s leading diagnostic companies to help enable global mass-testing, manufacturing over 30 million tests.
As we emerged from this unprecedented challenge, we have embarked upon a programme of major strategic growth that has seen us more than double our manufacturing capacity. We now offer a unique, flexible, and scalable development and manufacturing service to the diagnostic sector, and we want to get out there and tell people all about it!
Tell us a little about Biofortuna?
We describe ourselves as a contract development and manufacturing organisation. Our origins lie in diagnostic assay research and development, but our unique proposition today is our flexibility and scale as a contract manufacturing partner.
Our experience in development has seen us amass a wealth of knowledge in all aspects of assay design, but our real point of excellence is helping our customers to develop assays that are suitable for efficient, high volume commercial manufacture - and then doing exactly that in our new UK based, state-of-the-art manufacturing facility. Ultimately our service enables our customers to get assays to market faster and increase manufacturing throughput and efficiency.
What makes us unique though is our flexibility. We can offer a full end-to end solution from concept to commercialisation or we can tailor our support to meet our customers’ exact needs - from our genomics capability in DNA sequencing and genotyping, through assay formulation and stabilisation, to large scale manufacturing, fill and finish and stability storage – or any combination of these. We help people solve problems.
Give our readers an insight as to what they can expect at the Biofortuna stand?
Our experts will be on hand to discuss all aspects of our service and to get an understanding of our visitors’ issues and challenges. We will have samples of our customisable reagent beads and we will be delighted to discuss how lyophilising reagents as a bead can improve assay accuracy and obviate the need for cold chain storage.
But really our stand will reflect our overall approach. You won’t find a range of products that we are pushing, you’ll find a team of assay development and manufacturing experts who want to understand your challenges and solve your problems.
Who are you looking to connect with at this year’s show?
We want to engage with anyone who is designing, developing and/or manufacturing assays that wants to expand their contact network to include outsourcing options.
Biofortuna will be exhibiting on Stand C10. Med-Tech Innovation Expo takes place on 8-9th June at the NEC, Birmingham. To register, please visit www.med-techexpo.com.
